Skip to main content
Top

01-27-2017 | Gastroparesis | Book chapter | Article

3. Diabetic Gastroparesis

Authors: Aylin Tansel, Nisreen Husain

Publisher: Springer International Publishing

Abstract

Gastroparesis is defined as a chronic disorder characterized by delayed emptying of the stomach occurring in the absence of mechanical obstruction. It is a well-known and potentially serious complication of diabetes. Although gastroparesis was initially described in patients with type 1 diabetes, it is increasingly being recognized in patients with type 2 diabetes. Diabetic gastroparesis affects up to 40 % of patients with type 1 diabetes and up to 30 % of patients with type 2 diabetes [1, 2]. Diabetic gastroparesis generally affects patients with long-standing diabetes mellitus, and patients often have other diabetic complications such as retinopathy, neuropathy, or nephropathy. Gastroparesis can lead to poor glucose control, increased morbidity, and decreased quality of life. As the number of patients with diabetes increases, the number of diabetic patients with gastroparesis is increasing. For reasons that remain unclear, approximately 80 % of patients with gastroparesis are women [3]. Hospitalizations with gastroparesis as the primary diagnosis have increased 158 % from 1995 to 2004 [4]. Additionally, gastroparesis has the longest length of stay when compared with other upper gastrointestinal conditions [4]. This chapter will explore the clinical features, complications, diagnosis, management, and treatment options for gastroparesis.
Literature
1.
Lyrenås EB, Olsson EH, Arvidsson UC, Orn TJ, Spjuth JH. Prevalence and determinants of solid and liquid gastric emptying in unstable type I diabetes. Relationship to postprandial blood glucose concentrations. Diabetes Care. 1997;20:413–8.CrossRefPubMed
2.
Horowitz M, Harding PE, Maddox AF, Wishart JM, Akkermans LM, Chatterton BE, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32:151–9.CrossRefPubMed
3.
Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998;43:2398–404.CrossRefPubMed
4.
Wang YR, Fisher RS, Parkman HP. Gastroparesis-related hospitalizations in the United States: trends, characteristics, and outcomes, 1995–2004. Am J Gastroenterol. 2008;103:313–22.CrossRefPubMed
5.
Bytzer P, Talley NJ. Dyspepsia. Ann Intern Med. 2001;134(9 Pt 2):815–22.CrossRefPubMed
6.
Manuscript A. NIH public access. Gastroenterology 2011;14:997–1003.
7.
Wytiaz V, Homko C, Duffy F, Schey R, Parkman HP. Foods provoking and alleviating symptoms in gastroparesis: patient experiences. Dig Dis Sci. 2015;60:1052–8.CrossRefPubMed
8.
Halland M, Bharucha AE. Relationship between control of glycemia and gastric emptying disturbances in diabetes mellitus. Clin Gastroenterol Hepatol. 2016;14:929–36.CrossRefPubMed
9.
Gonlachanvit S, Hsu C-W, Boden GH, Knight LC, Maurer AH, Fisher RS, et al. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. Dig Dis Sci. 2003;48:488–97.CrossRefPubMed
10.
Bharucha AE, Kudva Y, Basu A, Camilleri M, Low PA, Vella A, et al. Relationship between glycemic control and gastric emptying in poorly controlled type 2 diabetes. Clin Gastroenterol Hepatol. 2015;13:466–76.e1.CrossRefPubMed
11.
Abell TL, Camilleri M, Donohoe K, Hasler WL, Lin HC, Maurer AH, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American neurogastroenterology and motility society and the society of nuclear medicine. Am J Gastroenterol. 2008;103:753–63.CrossRefPubMed
12.
Marathe CS, Rayner CK, Jones KL, Horowitz M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care. 2013;36:1396–405.CrossRefPubMedPubMedCentral
13.
Parkman HP, McCallum RW, Fass R. Clinical roundtable monograph treatment of patients with diabetic faculty. Postgraduate Institute for Medicine. 2009. www.​gastroenterology​andhepatology.​net/​files/​2013/​05/​gh1009_​sup181.​pdf. Accessed on 20 Sept 2016.
14.
Bharucha AE, Batey-Schaefer B, Cleary PA, Murray JA, Cowie C, Lorenzi G, et al. Delayed gastric emptying is associated with early and long-term hyperglycemia in type 1 diabetes mellitus. Gastroenterology. 2015;149:330–9.CrossRefPubMedPubMedCentral
15.
Kuo B, McCallum RW, Koch KL, Sitrin MD, Wo JM, Chey WD, et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther. 2008;27:186–96.CrossRefPubMed
16.
Revicki DA, Camilleri M, Kuo B, Szarka LA, McCormack J, Parkman HP. Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD). Neurogastroenterol Motil. 2012;24:456–63. e215–6CrossRefPubMed
17.
Sellin JH, Chang EB. Therapy insight: gastrointestinal complications of diabetes – pathophysiology and management. Nat Clin Pract Gastroenterol Hepatol. 2008;5:162–71.CrossRefPubMed
18.
Bujanda L. The effects of alcohol consumption upon the gastrointestinal tract. Am J Gastroenterol. 2000;95:3374–82.CrossRefPubMed
19.
Miller G, Palmer KR, Smith B, Ferrington C, Merrick MV. Smoking delays gastric emptying of solids. Gut. 1989;30:50–3.CrossRefPubMedPubMedCentral
20.
Kuo P, Rayner CK, Jones KL, Horowitz M. Pathophysiology and management of diabetic gastropathy a guide for endocrinologists. Drugs. 2007;67:1671–87.CrossRefPubMed
21.
Perkel MS, Moore C, Hersh T, Davidson ED. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Dig Dis Sci. 1979;24:662–6.CrossRefPubMed
22.
Snape WJ, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med. 1982;96:444–6.CrossRefPubMed
23.
McCallum RW, Ricci DA, Rakatansky H, Behar J, Rhodes JB, Salen G, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6:463–7.CrossRefPubMed
24.
Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol. 1985;7:25–32.CrossRefPubMed
25.
Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31:11–9.CrossRefPubMed
26.
Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray reduces symptoms of gastroparesis in women, but not men, with diabetes: results of a phase 2B randomized study. Clin Gastroenterol Hepatol. 2015;13:1256–63.e1.CrossRefPubMed
27.
Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;9(351):1089–96.CrossRef
28.
Camilleri M. Clinical practice diabetic gastroparesis. N Engl J Med. 2007;356:820–9.CrossRefPubMed
29.
Parkman HP, Van Natta ML, Abell TL, McCallum RW, Sarosiek I, Nguyen L, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA. 2013;310:2640–9.CrossRefPubMedPubMedCentral
30.
Lacy BE, Crowell MD, Schettler-Duncan A, Mathis C, Pasricha PJ. The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus. Diabetes Care. 2004;27:2341–7.CrossRefPubMed
31.
Bromer MQ, Friedenberg F, Miller LS, Fisher RS, Swartz K, Parkman HP. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc. 2005;61:833–9.CrossRefPubMed
32.
Arts J, van Gool S, Caenepeel P, Verbeke K, Janssens J, Tack J. Influence of intrapyloric botulinum toxin injection on gastric emptying and meal-related symptoms in gastroparesis patients. Aliment Pharmacol Ther. 2006;24:661–7.CrossRefPubMed
33.
Woodward MN, Spicer RD. Intrapyloric botulinum toxin injection improves gastric emptying. J Pediatr Gastroenterol Nutr. 2003;37:201–2.CrossRefPubMed
34.
Ezzeddine D, Jit R, Katz N, Gopalswamy N, Bhutani MS. Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest Endosc. 2002;55:920–3.CrossRefPubMed
35.
Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol. 2008;103:416–23.CrossRefPubMed
36.
Arts J, Holvoet L, Caenepeel P, Bisschops R, Sifrim D, Verbeke K, et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther. 2007;26:1251–8.CrossRefPubMed
37.
Camiller M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108:18–38.CrossRef
38.
Maple JT, Petersen BT, Baron TH, Gostout CJ, Wong Kee Song LM, Buttar NS. Direct percutaneous endoscopic jejunostomy: outcomes in 307 consecutive attempts. Am J Gastroenterol. 2005;100:2681–8.CrossRefPubMed
39.
Heckert J, Sankineni A, Hughes WB, Harbison S, Parkman H. Gastric electric stimulation for refractory gastroparesis: a prospective analysis of 151 patients at a single center. Dig Dis Sci. 2015;61:168–75.CrossRefPubMed
40.
O’Grady G, Egbuji JU, Du P, Cheng LK, Pullan AJ, Windsor JA. High-frequency gastric electrical stimulation for the treatment of gastroparesis: a meta-analysis. World J Surg. 2009;33:1693–701.CrossRefPubMedPubMedCentral
41.
Toro JP, Lytle NW, Patel AD, Davis SS, Christie JA, Waring JP, et al. Efficacy of laparoscopic pyloroplasty for the treatment of gastroparesis. J Am Coll Surg. 2014;218:652–60.CrossRefPubMed
42.
Hibbard ML, Dunst CM, Swanström LL. Laparoscopic and endoscopic pyloroplasty for gastroparesis results in sustained symptom improvement. J Gastrointest Surg. 2011;15:1513–9.CrossRefPubMed
43.
Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol. 2003;98:2122–9.CrossRefPubMed
44.
Camilleri M, Malagelada JR. Abnormal intestinal motility in diabetics with the gastroparesis syndrome. Eur J Clin Investig. 1984;14:420–7.CrossRef
45.
Yang M, Li X, Liu S, Li Z, Xue M, Gao D, et al. Meta-analysis of acupuncture for relieving non-organic dyspeptic symptoms suggestive of diabetic gastroparesis. BMC Complement Altern Med. 2013;13:311.CrossRefPubMedPubMedCentral
46.
Hobson R, Farmer AD, Dewit OE, O’Donnell M, Hacquoil K, Robertson D, et al. The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial. Neurogastroenterol Motil. 2015;27:1629–37.CrossRefPubMed
47.
Barshop K, Kuo B. The investigational drug camicinal for the treatment of gastroparesis. Expert Opin Investig Drugs. 2015;24:133–40.CrossRefPubMed
48.
Hellström P, Tack J, Johnson L, Hacqouil K, Barton M, Richards D, et al. The pharmacodynamics, safety, and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying. Br J Pharmacol. 2016;173:1768–77.CrossRefPubMed
49.
Camilleri M. Novel diet, drugs, and gastric interventions for gastroparesis. Clin Gastroenterol Hepatol. 2016;14:1072–80.CrossRefPubMed
50.
Camilleri M, Acosta A. Emerging treatments in neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist. Neurogastroenterol Motil. 2015;27:324–32.CrossRefPubMed
51.
Acosta A, Camilleri M. Prokinetics in gastroparesis. Gastroenterol Clin North Am Elsevier Inc. 2015;44:97–111.CrossRef
52.
Sadiya A. Nutritional therapy for the management of diabetic gastroparesis: clinical review. Diabetes Metab Syndr Obes. 2012;5:329–35.CrossRefPubMedPubMedCentral
53.
Alam U, Asghar O, Malik RA. Diabetic gastroparesis: therapeutic options. Diabetes Ther. 2010;1:32–43.CrossRefPubMedPubMedCentral
54.
Drucker D, Nauck M. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.CrossRefPubMed

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »